10-Q: Milestone Scientific Q1 2026 Results Show Revenue Stability

Milestone Scientific reported stable revenue for Q1 2026, with a decrease in dental sales offset by growth in medical products, while significantly reducing operating expenses.

Summary

• Total product sales for the first quarter of 2026 were approximately $2.2 million, a slight decrease of 3% from the prior year's $2.2 million.
• Dental product revenue decreased by 6% to $2.05 million, attributed to lower international distributor demand influenced by geopolitical conditions.
• Medical revenue saw significant growth, increasing by 110% to $108,000 from $51,000 in the prior year, reflecting early adoption of medical products.
• Gross profit decreased by 5% to $1.56 million, with a gross margin of 72.3% compared to 73.8% in the prior year, impacted by product mix, lower sales volume, and cost pressures.
• Selling, general, and administrative (SG&A) expenses were significantly reduced by 27.2% to $2.37 million, primarily due to lower professional fees and marketing expenditures.
• Research and development expenses were eliminated in the current period, compared to $369,000 in the prior year.
• The net loss improved substantially to $839,853 from $1.99 million in the prior year, an improvement of approximately $1.2 million.
• Net cash provided by operating activities was $86,842, a significant improvement from a net cash used of $1.0 million in the prior year.
• The company completed a private placement on April 20, 2026, raising approximately $2.15 million in gross proceeds.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment, primarily due to the ongoing going concern issues and delisting risk, despite operational improvements and a successful capital raise.

Positives

• Significant reduction in operating expenses, particularly SG&A, by 27.2% ($884,000).
• Substantial improvement in net loss, decreasing by 58% to $839,853 from $1.99 million.
• Positive net cash flow from operating activities of $86,842, a marked improvement from negative $1.0 million in the prior year.
• Strong growth in the Medical segment, with revenue increasing by 110% to $108,000.
• Successful completion of a private placement raising $2.15 million, improving liquidity.
• The company has a purchase order in April 2026 indicating renewed activity in the China market.

Negatives

• Overall product sales decreased by 3% to $2.16 million.
• Dental product revenue decreased by 6% to $2.05 million.
• Gross margin declined slightly to 72.3% from 73.8%, impacted by product mix, lower sales volume, and cost pressures.
• Continued operating losses and an accumulated deficit raise substantial doubt about the company's ability to continue as a going concern.
• The company's common stock is at risk of delisting from NYSE American by April 8, 2027, due to not meeting minimum stockholders' equity requirements.
• The April 2026 private placement and outstanding convertible notes create significant dilution risk for existing stockholders.

Risks

• The company has incurred significant losses and continues to experience operating losses, raising substantial doubt about its ability to continue as a going concern.
• A significant portion of revenue is derived from dental products; any decline in demand, increased competition, or distribution disruptions could be materially adverse.
• Commercialization of medical products, including the CompuFlo Epidural System, may not achieve expected adoption due to reimbursement uncertainty, clinician adoption rates, and competition.
• Changes to U.S. tariff and import/export regulations, particularly concerning sourcing from China, could adversely affect the business.
• Government actions on tariffs and research funding may impede research and capital raising efforts.
• Geopolitical tensions and instability in international markets could disrupt distribution and negatively impact international sales.
• Reliance on Chinese manufacturers for products and components, coupled with U.S.-China trade tensions, poses risks to supply chain and market access.
• Operating results may fluctuate due to changes in product mix and demand.
• The company relies on key personnel and consultants; loss of key individuals could hinder business strategy execution.
• The company's common stock may be delisted from NYSE American if it fails to regain compliance with listing standards by April 8, 2027.
• The April 2026 private placement and outstanding convertible instruments create significant dilution risk for existing stockholders.

Future Outlook

The company believes its current cash resources, expected collections, and financing proceeds will be sufficient for near-term operations. However, its ability to continue as a going concern depends on generating sufficient revenue, managing operating expenses, and obtaining additional financing if necessary. There is no assurance that additional financing will be available on acceptable terms.

Management Comments

• The Company continues to focus on expanding adoption of its DPS technology platform, advancing commercialization of its Medical segment, and maintaining disciplined cost management while supporting targeted growth initiatives.
• Overall, the Company maintained a relatively stable revenue base, with modest variability primarily attributable to external market conditions.
• The Company continues to evaluate its research and development priorities and may make targeted investments in future periods to support product enhancements, new applications, and long-term growth initiatives.

Industry Context

StockSavvy.ai notes that Milestone Scientific's Q1 2026 results reflect a challenging but stabilizing environment for medical device companies. The shift in revenue mix towards the Medical segment, despite overall revenue flatness, indicates a strategic pivot, while significant cost reductions demonstrate a focus on operational efficiency. The ongoing going concern issues and NYSE delisting risk highlight the critical need for successful commercialization of new products and continued access to capital in a competitive landscape.

Comparison to Industry Standards

• The gross margin of 72.3% is generally strong for a medical device company, though it has slightly declined from the prior year.
• The significant reduction in SG&A expenses (27.2%) is a positive sign of cost control, which is crucial for smaller companies in the medical device sector aiming for profitability.
• The company's net loss per share of $(0.01) is typical for early-stage or turnaround companies in the medical technology space, where R&D and market adoption costs are high.
• The reliance on a private placement for liquidity is common for companies facing going concern issues, but the terms and potential dilution are key factors for investors to monitor.

Related Party Transactions

• Purchases from United Systems (supplier of handpieces) were approximately $249,000 for Q1 2026.
• As of March 31, 2026, Milestone Scientific owed United Systems approximately $801,000.
• Royalty expense paid to the Director of Clinical Affairs totaled approximately $96,000 for Q1 2026.
• Consulting fees paid to the Director of Clinical Affairs totaled approximately $25,000 for Q1 2026.
• Accrued royalties owed to the Director of Clinical Affairs were approximately $384,000 as of March 31, 2026.
• Expenses related to Mr. Osser's Employment Agreement were $50,000 for Q1 2026.
• Expenses related to Mr. Osser's Consulting Agreement were $50,000 for Q1 2026.
• University Pain Medicine Center (STEMMEE), led by Director Dr. D. Demesmin, purchased medical products totaling approximately $6,000 for Q1 2026.
• Amounts owed by STEMMEE were approximately $22,300 as of March 31, 2026.
• No consulting expense was recorded for Mr. Haverhals in Q1 2026.
• As of December 31, 2025, the Company owed Mr. Haverhals approximately $89,000, of which he waived approximately $66,000 subsequent to December 31, 2025.
• Convertible notes totaling $800,000 were issued to directors Neal Goldman, Benedetta Casamento, and Didier Demesmin in April 2025.
• As part of the April 2026 private placement, these directors reduced their outstanding principal by $351,000 in total.
• BP4 S.r.l. is a significant shareholder and related party; an MOU was amended on March 31, 2026, concerning lock-up agreements and offering facilitation.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the April 2026 private placement and outstanding convertible notes. Risk of delisting from NYSE American could negatively impact share price and liquidity.
• Creditors/Suppliers: Increased accounts payable and related party payables, with significant amounts owed to suppliers like United Systems. The company's liquidity is crucial for timely payments.
• Management/Employees: Continued focus on cost management and operational efficiency. Stock-based compensation is recognized as an expense.
• Distributors: Lower international distributor demand impacted Q1 2026 revenue. Geopolitical conditions are cited as a factor.
• Customers: Stable revenue base suggests continued demand for dental products, while medical product adoption is in early stages.

Next Steps

• Continue to focus on expanding adoption of DPS technology platform.
• Advance commercialization of the Medical segment.
• Maintain disciplined cost management.
• Support targeted growth initiatives.
• Evaluate potential targeted investments in product enhancements and new applications.
• Achieve required equity thresholds to regain compliance with NYSE American listing standards by April 8, 2027.
• Potentially exercise warrants from the April 2026 private placement to raise additional capital.

Key Dates

Recommendation

The company shows signs of operational improvement with reduced losses and positive operating cash flow, alongside a successful capital raise. However, the persistent going concern issues, risk of delisting from NYSE American, and significant dilution potential from equity instruments warrant a cautious approach. A 'hold' recommendation reflects the balance between these improving operational metrics and the substantial financial and market risks.

Keywords

Milestone Scientific, Form 10-Q, Quarterly Report, Dental Products, Medical Devices, CompuFlo Epidural System, STA Single Tooth Anesthesia System, Financial Results, Revenue, Net Loss, Going Concern, Private Placement, Dilution